Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Press Release for the Quarter ended 31st March, 2026".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Pharmaceuticals reported resilient Q4 FY26 results with revenue up 4% YoY to Rs 1,848 Cr and PAT up 29% YoY to Rs 203 Cr. Pre-R&D EBITDA grew 8% to Rs 455 Cr with a margin of 25%. India Branded Business contributed Rs 568 Cr (up 4%), US Formulations grew 11% to Rs 564 Cr, Ex-US Generics was at Rs 369 Cr, and API Business stood at Rs 347 Cr. The company launched its US Branded Business through Alembic Therapeutics with Pivya for uncomplicated urinary tract infections. For the full year FY26, total revenue grew 10% to Rs 7,345 Cr, with US Formulations up 13% and Ex-US Generics up 20%.
Strong bottom-line performance with 29% PAT growth and improved margins indicates operational efficiency gains. The entry into US Branded Business through Pivya launch opens a new growth avenue. Overall healthy segment performance across geographies suggests continued business momentum.